This filing is a routine employee communication with no new deal terms or financial guidance. The Q1 revenue growth is strong but already disclosed. Monitor the definitive proxy statement for shareholder vote details and any potential competing bids. The stock will likely trade on the acquisition spread until closing.
Price Chart
Executive Summary
Catalyst Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) containing an employee update email from the CEO regarding the pending acquisition by Angelini Pharma. The email confirms Q1 2026 revenues of $149.4 million (28.2% YoY growth) and reiterates the expected closing in Q3 2026. This is a routine communication to employees and does not contain new material information for shareholders beyond what was previously disclosed.
Key Facts
- Filing is a DEFA14A containing an employee email from Catalyst CEO regarding the Angelini Pharma acquisition.
- Q1 2026 revenues were $149.4 million, representing 28.2% year-over-year growth, including $135.6 million from FIRDAPSE and AGAMREE.
- Transaction expected to close in Q3 2026; integration planning underway.
- Catalyst will enter a quiet period, continuing quarterly earnings reports but suspending investor calls and conferences.
- Town hall scheduled for May 27, 2026 with Angelini Pharma CEO.
Financial Impact
Q1 2026 revenues of $149.4 million, up 28.2% YoY; no new financial guidance or deal terms provided.
Risk Factors
- Transaction may not close if stockholder approval is not obtained or regulatory conditions are not satisfied.
- Integration risks post-closing could affect combined entity performance.
- Quiet period limits management communication, increasing uncertainty for investors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-218309 |
| Document: 0001193125-26-218309-index-headers.html | 0001193125-26-218309 |
| Document: 0001193125-26-218309-index.html | 0001193125-26-218309 |
| Document: 0001193125-26-218309.txt | 0001193125-26-218309 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access